Metabolic Modification in Gastrointestinal Cancer Stem Cells: Characteristics and Therapeutic Approaches

Journal of Cellular Physiology

Volumn 231, Issue 10, 2016, Pages 2081-2087

  Di Francesco, Angela Maria ^a   Toesca, Amelia ^b   Cenciarelli, Carlo ^c   Giordano, Antonio ^d   Gasbarrini, Antonio ^a   Puglisi, Maria Ausiliatrice ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^d TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; ANTINEOPLASTIC AGENT; METFORMIN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE;

CANCER STEM CELL; CELL METABOLISM; CLINICAL TRIAL (TOPIC); DIGESTIVE SYSTEM CANCER; ENZYME INHIBITION; GLYCOLYSIS; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; STEM CELL SELF-RENEWAL; TARGET CELL;

EID: 84975045692     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25318     Document Type: Review

References (98)

1. Akao Y, Noguchi S, Iio A, Kojima K, Takagi T, Naoe T. 2011. Dysregulation of microRNA-34a expression causes drug resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett 300:197–204.
2. Asaka R, Miyamoto T, Yamada Y, Ando H, Mvunta DH, Kobara H, Shiozawa T. 2015. Sirtuin 1 promotes the growth and cisplatin resistance of endometrial carcinoma cells: A novel therapeutic target. Lab Invest 95:1363–1373.
3. Ben-Neriah Y, Karin M. 2011. Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 12:715–723.
4. Cacciatore S, Loda M. 2015. Innovation in metabolomics to improve personalized healthcare. Ann N Y Acad Sci 1346:57–62.
5. Cairns RA, Harris IS, Mak TW. 2011. Regulation of cancer cell metabolism. Nat Rev Cancer 11:85–95.
6. Capparelli C, Whitaker-Menezes D, Guido C, Balliet R, Pestell TG, Howell A, Sneddon S, Pestell RG, Martinez-Outschoorn U, Lisanti MP, Sotgia F. 2012. CTGF drives autophagy, glycolysis and senescence in cancer associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle 11:2272–2284.
7. Chen CT, Hsu SH, Wei YH. 2010. Upregulation of mitochondrial function and antioxidant defense in the differentiation of stem cells. Biochim Biophys Acta 1800:257–263.
8. Chen CT, Shih YR, Kuo TK, Lee OK, Wei YH. 2008. Coordinated changes of mitochondrial biogenesis and antioxidant enzymes during osteogenic differentiation of human mesenchymal stem cells. Stem Cells 26:960–968.
9. Chen X, Hu C, Zhang W, Shen Y, Wang J, Hu F, Yu P. 2015. Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro. P Tumour Biol 36:9873–9883.
10. Chiaradonna F, Moresco RM, Airoldi C, Gaglio D, Palorini R, Nicotra F, Messa C, Alberghina L. 2012. From cancer metabolism to new biomarkers and drug targets. Biotechnol Adv 30:30–51.
11. Chiba T, Suzuki E, Yuki K, Zen Y, Oshima M, Miyagi S, Saraya A, Koide S, Motoyama T, Ogasawara S, Ooka Y, Tawada A, Nakatsura T, Hayashi T, Yamashita T, Kaneko S, Miyazaki M, Iwama A, Yokosuka O. 2014. Disulfirameradicates tumorinitiating hepatocellular carcinoma cells in ROS-p38 MAPKpathway-dependent and -independent manners. PLoS ONE 9:e84807.
12. Chow AK, Ng L, Lam CS, Wong SK, Wan TM, Cheng NS, Yau TC, Poon RT, Pang RW. 2013. The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS ONE 8:e78675.
13. Cichon MA, Radisky DC. 2014. ROS-induced epithelial-mesenchymal transition in mammary epithelial cells is mediated by NF-kB-dependent activation of Snail. Oncotarget 5:2827–2838.
14. Courtnay R, Ngo DC, Malik N, Ververis K, Tortorella SM, Karagiannis TC. 2015. Cancer metabolism and the warburg effect: The role of HIF-1 and PI3K. Mol Biol Rep 42:841–851.
15. Dando I, Cordani M, Dalla Pozza E, Biondani G, Donadelli M, Palmieri M. 2015. Antioxidant mechanisms and ROS-related microRNAs in cancer stem cells. Oxid Med Cell Longev 425708.
16. De Carolis S, Bertoni S, Nati M, D'Anello L, Papi A, Tesei A, Cricca M, Bonafé M. 2015. Carbonic anhydrase 9 mRNA/microRNA34a interplay in hypoxic human mammospheres. J Cell Physiol DOI: 10.1002/jcp.25245
17. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB. 2007. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104:19345–19350.
18. Denise C, Paoli P, Calvani M, Taddei ML, Giannoni E, Kopetz S, Kazmi SM, Pia MM, Pettazzoni P, Sacco E, Caselli A, Vanoni M, Landriscina M, Cirri P, Chiarugi P. 2015. 5-Fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits. Oncotarget 6:41706–41721.
19. Di Gangi IM, Mazza T, Fontana A, Copetti M, Fusilli C, Ippolito A, Mattivi F, Latiano A, Andriulli A, Vrhovsek U, Pazienza V. 2015. Metabolomic profile in pancreatic cancer patients: A consensusbased approach to identify highly discriminating metabolites. Oncotarget DOI: 10.18632/oncotarget.6808
20. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, Clarke MF. 2009. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458:780–783.
21. Ding S, Li C, Cheng N, Cui X, Xu X, Zhou G. 2015. Redox regulation in cancer stem cells. Oxid Med Cell Longev 750798. DOI: 10.1155/2015/750798 Epub.
22. Estrela JM, Ortega A, Obrador E. 2006. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43:143–181.
23. Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, Misuraca KL, Lathia JD, Forrester MT, Lee J, Stamler JS, Goldman SA, Bredel M, McLendon RE, Sloan AE, Hjelmeland AB, Rich JN. 2011. Glioma stem cell proliferation and tumour growth are promoted by nitric oxide synthase-2. Cell 8:53–66.
24. Fiaschi T, Marini A, Giannoni E, Taddei ML, Gandellini P, De Donatis A, Lanciotti M, Serni S, Cirri P, Chiarugi P. 2012. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res 72:5130–5140.
25. Giannoni E, Parri M, Chiarugi P. 2012. EMT and oxidative stress: A bidirectional interplay affecting tumor malignancy. Antioxid Redox Signal 16:1248–1263.
26. Gou S, Cui P, Li X, Shi P, Liu T, Wang C. 2013. Low concentrations of metformin selectively inhibit CD133(+) cell proliferation in pancreatic cancer and have anticancer action. PLoS ONE 8:e63969.
27. Gritti M, Würth R, Angelini M, Barbieri F, Peretti M, Pizzi E, Pattarozzi A, Carra E, Sirito R, Daga A, Curmi PM, Mazzanti M, Florio T. 2014. Metformin repositioning as antitumoral agent: Selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current. Oncotarget 5:11252–11268.
28. Hart PC, Mao M, de Abreu AL, Ansenberger-Fricano K, Ekoue DN, Ganini D, Kajdacsy-Balla A, Diamond AM, Minshall RD, Consolaro ME, Santos JH, Bonini MG. 2015. MnSOD upregulation sustains the Warburg effect via mitochondrial ROS and AMPK-dependent signalling in cancer. Nat Commun 6:6053.
29. He J, Wang K, Zheng N, Qiu Y, Xie G, Su M, Jia W, Li H. 2015. Metformin suppressed the proliferation of LoVo cells and induced a time-dependent metabolic and transcriptional alteration. Sci Rep Nov 5:17423.
30. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. 2009. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69:7507–7511.
31. Hirsh HA, Iliopoulos D, Struhl K. 2013. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci USA 110:972–977.
32. Hsieh SC, Tsai JP, Yang SF, Tang MJ, Hsieh YH. 2014. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression. Amino Acids 46:2809–2822.
33. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM. 2009. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69:3382–3389.
34. Iliopoulos D, Hirsch HA, Struhl K. 2011. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 71:3196–3201.
35. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba H, Saya H. 2011. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(−) and thereby promotes tumor growth. Cancer Cell 19:387–400.
36. Janzer A, German NJ, Gonzalez-Herrera KN, Asara JM, Haigis MC, Struhl K. 2014. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc Natl Acad Sci USA 111:10574–10579.
37. Jež M, Rožman P, Ivanović Z, Bas T. 2015. Concise review: The role of oxygen in hematopoietic stem cell physiology. J Cell Physiol 230:1999–2005.
38. Jin L, Alesi GN, Kang S. 2015. Glutaminolysis as a target for cancer therapy. Oncogene DOI: 10.1038/onc.2015.447
39. Kareva I. 2011. Prisoner's dilemma in cancer metabolism. PLoS ONE 6:e28576.
40. Keith B, Johnson RS, Simon MC. 2012. HIF1a and HIF2a: Sibling rivalry in hypoxic tumor growth and progression. Nat Rev Cancer 12:9–22.
41. Khorrami S, Zavaran Hosseini A, Mowla SJ, Malekzadeh R. 2015. Verification of ALDH activity as a biomarker in colon cancer stem cells-derived HT-29 cell line. Iran J Cancer Prev 8:e3446.
42. Kim HB, Lee SH, Um JH, Kim MJ, Hyun SK, Gong EJ, Oh WK, Kang CD, Kim SH. 2015. Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition. Int J Biol Sci 11:923–934.
43. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. 2006. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metabolism 3:177–185.
44. Kim YS, Kang MJ, Cho YM. 2013. Low production of reactive oxygen species and high DNA repair: Mechanism of radioresistance of prostate cancer stem cells. Anticancer Res 33:4469–4474.
45. Kobayashi CI, Suda T. 2012. Regulation of reactive oxygen species in stem cells and cancer stem cells. J Cell Physiol 227:421–430.
46. Li L, Osdal T, Ho Y, Chun S, McDonald T, Agarwal P, Lin A, Chu S, Qi J, Li L, Hsieh YT, Dos Santos C, Yuan H, Ha TQ, Popa M, Hovland R, Bruserud O, Gjertsen BT, Kuo YH, Chen W, Lain S, McCormack E, Bhatia R. 2014. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell 15:431–446.
47. Liu PP, Liao J, Tang ZJ, Wu WJ, Yang J, Zeng ZL, Hu Y, Wang P, Ju HQ, Xu RH, Huang P. 2014. Metabolic regulation of cancer cell side population by glucose through activation of the akt pathway. Cell Death Differ 21:124–135.
48. Lonardo E, Cioffi M, Sancho P, Crusz S, Heeschen C. 2015. Studying pancreatic cancer stem cell characteristics for developing new treatment strategies. J Vis Exp DOI: 10.3791/52801
49. Luengo A, Sullivan LB, Heiden MG. 2014. Understanding the complex-I-ty of metformin action: Limiting mitochondrial respiration to improve cancer therapy. BMC Biol 12:82.
50. Ma W, Xiao GG, Mao J, Lu Y, Song B, Wang L, Fan S, Fan P, Hou Z, Li J, Yu X, Wang B, Wang H, Wang H, Xu F, Li Y, Liu Q, Li L. 2015. Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness. Oncotarget 6:10432–10444.
51. Mandai M, Amano Y, Yamaguchi K, Matsumura N, Baba T, Konishi I,. 2015. Ovarian clear cell carcinoma meets metabolism; HNF-1β confers survival benefits through the Warburg effect and ROS reduction. Oncotarget 6:30704–30714.
52. Mao B, Hu F, Cheng J, Wang P, Xu M, Yuan F, Meng S, Wang Y, Yuan Z, Bi W. 2014. SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene 33:1468–1474.
53. Martinez-Outschoorn UE, Pavlides S, Howell A, Pestell RG, Tanowitz HB, Sotgia F, Lisanti MP. 2011. Stromal-epithelial metabolic coupling in cancer: Integrating autophagy and metabolism in the tumor microenvironment. Int J Biochem Cell Biol 43:1045–1051.
54. McCord AM, Jamal M, Shankavarum UT, Lang FF, Camphausen K, Tofilon PJ. 2009. Physiologic oxygen concentration enhances the stem like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 7:489–497.
55. Menendez JA, Alarcón T. 2014. Metabostemness: A new cancer hallmark. Front Oncol 4:262.
56. Menendez JA, Joven J, Cufí S, Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Martin-Castillo B, López-Bonet E, Alarcón T, Vazquez-Martin A. 2013. The warburg effect version 2.0: Metabolic reprogramming of cancer stem cells. Cell Cycle 8:1166–1179.
57. Miller RA, Chu Q, Xie J, Foretz, Viollet B, Birnbaum MJ. 2013. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494:256–260.
58. Nangia-Makker P, Yu Y, Vasudevan A, Farhana L, Rajendra SG, Levi E, Majumdar AP. 2014. Metformin: A potential therapeutic agent for recurrent colon cancer. PLoS ONE 9:e84369.
59. Nesbitt H, Browne G, O'Donovan KM, Byrne NM, Worthington J, McKeown SR, McKenna DJ. 2016. Nitric oxide up-regulates RUNX2 in LNCaP prostate tumours: Implications for tumour growth in vitro and in vivo. J Cell Physiol 231:473–482.
60. Ng F, Tang BL. 2013. Sirtuins' modulation of autophagy. J Cell Physiol 228:2262–2270.
61. Niu F, Li Y, Lai FF, Ni L, Ji M, Jin J, Yang HZ, Wang C, Zhang DM, Chen XG. 2015. LB-1 Exerts antitumor activity in pancreatic cancer by inhibiting HIF-1α and Stat3 signaling. J Cell Physiol 230:2212–2223.
62. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O. 2009. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220–231.
63. Paldino E, Tesori V, Casalbore P, Gasbarrini A, Puglisi MA. 2014. Tumor initiating cells and chemoresistance: Which is the best strategy to target colon cancer stem cells? Biomed Res Int 2014:859871.
64. Parks SK, Mazure NM, Counillon L, Pouysségur J. 2013. Hypoxia promotes tumor cell survival in acidic conditions by preserving ATP levels. J Cell Physiol 228:1854–1862.
65. Pozza ED, Donadelli M, Costanzo C, Zaniboni T, Dando I, Franchini M, Arpicco S, Scarpa A, Palmieri M. 2011. Gemcitabine response in pancreatic adenocarcinoma cells is sinergistically enhanced by dithiocarbamate derivatives. Free Radic Biol Med 50:926–933.
66. Puglisi MA, Cenciarelli C, Tesori V, Cappellari M, Martini M, Di Francesco AM, Giorda E, Carsetti R, Ricci-Vitiani L, Gasbarrini A. 2015. High nitric oxide production, secondary to inducible nitric oxide synthase expression, is essential for regulation of the tumour-initiating properties of colon cancer stem cells. J Pathol 236:479–490.
67. Puglisi MA, Tesori V, Lattanzi W, Gasbarrini GB, Gasbarrini A. 2013. Colon cancer stem cells: Controversies and perspectives. World J Gastroenterol 19:2997–3006.
68. Saito T, Chiba T, Yuki K, Zen Y, Oshima M, Koide S, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Tada M, Kanai F, Takiguchi Y, Iwama A, Yokosuka O. 2013. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS ONE 8:e70010.
69. Salminen A, Kaarniranta K. 2010. Glycolysis links p53 function with NF-kappaB signaling: Impact on cancer and aging process. J Cell Physiol 224:1–6.
70. Salnikov AV, Liu L, Platen M, Gladkich J, Salnikova O, Ryschich E, Mattern J, Moldenhauer G, Werner J, Schemmer P, Büchler MW, Herr I. 2012. Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential. PLoS ONE 7:e46391.
71. Santoyo-Ramos P, Likhatcheva M, García-Zepeda EA, Castañeda-Patlán MC, Robles-Flores M. 2014. Hypoxia-inducible factors modulate the stemness and malignancy of colon cancer cells by playing opposite roles in canonical Wnt signaling. PLoS ONE 9:e112580.
72. Semenza GL. 2012. Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33:207–214.
73. Sermeus A, Rebucci M, Fransolet M, Flamant L, Desmet D, Delaive E, Arnould T, Michiels C. 2013. Differential effect of hypoxia on etoposide-induced DNA damage response and p53 regulation in different cell types. J Cell Physiol 228:2365–2376.
74. Sharma BK, Kolhe R, Black SM, Keller JR, Mivechi NF, Satyanarayana A. 2015. Inhibitor of differentiation 1 transcription factor promotes metabolic reprogramming in hepatocellular carcinoma cells. FASEB J DOI: 10.1096/fj.15-277749
75. Shen M, Zhang Z, Ratnam M, Dou QP. 2014. The interplay of AMP-activated protein kinase and androgen receptor in prostate cancer cells. J Cell Physiol 229:688–695.
76. Shi X, Zhang Y, Zheng J, Pan J. 2012. Reactive oxygen species in cancer stem cells. Antioxid Redox Signal 16:1215–1228.
77. Shimojo Y, Akimoto M, Hisanaga T, Tanaka T, Tajima Y, Honma Y, Takenaga K. 2013. Attenuation of reactive oxygen species by antioxidants suppresses hypoxia induced epithelial-mesenchymal transition and metastasis of pancreatic cancer cells. Clin Exp Metastasis 30:143–154.
78. Shuch B, Linehan WM, Srinivasan R. 2013. Aerobic glycolysis: A novel target in kidney cancer. Expert Rev Anticancer Ther 13:711–719.
79. Silvestri A, Palumbo F, Rasi I, Posca D, Pavlidou T, Paoluzi S, Castagnoli L, Cesareni G. 2015. Metformin induces apoptosis and downregulates pyruvate kinase M2 in breast cancer cells only when grown in nutrient-poor conditions. PLoS ONE 10:e0136250.
80. Singh S, Arcaroli J, Chen Y, Thompson DC, Messersmith W, Jimeno A, Vasiliou V. 2015. ALDH1B1 is crucial for colon tumorigenesis by modulating Wnt/β-Catenin, notch and PI3K/Akt signaling pathways. PLoS ONE 10:e0121648.
81. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, Dewhirst MW. 2008. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118:3930–3942.
82. Talarico G, Orecchioni S, Dallaglio K, Reggiani F, Mancuso P, Calleri A, Gregato G, Labanca V, Rossi T, Noonan DM, Albini A, Bertolini F. 2016. Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. Sci Rep 6:18673.
83. Thompson CB. 2011. Rethinking the regulation of cellular metabolism. Cold Spring Harb Symp Quant Biol 76:23–29.
84. Tomoko S, Tetsuhiro C, Kaori Y, Yoh Z, Motohiko O, Shuhei K, Tenyu M, Sadahisa O, Eiichiro S, Yoshihiko O, Akinobu T, Motohisa T, Fumihiko K, Yuichi T, Atsushi I, Osamu Y. 2013. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS ONE 8:e70010.
85. Ullman TA, Itzkowitz SH. 2011. Intestinal inflammation and cancer. Gastroenterology 140:1807–1816.
86. Vellinga TT, Borovski T, de Boer VC, Fatrai S, van Schelven S, Trumpi K, Verheem A, Snoeren N, Emmink BL, Koster J, Rinkes IH, Kranenburg O. 2015. SIRT1/PGC1α-dependent increase in oxidative phosphorylation supports chemotherapy resistance of colon cancer. Clin Cancer Res 21:2870–2879.
87. Vincent Z, Urakami K, Maruyama K, Yamaguchi K, Kusuhara M. 2014. CD133-positive cancer stem cells from Colo205 human colon adenocarcinoma cell line show resistance to chemotherapy and display a specific metabolomic profile. Genes Cancer 5:250–260.
88. Warburg O. 1956. On the origin of cancer cells. Science 123:309–314.
89. Wenner CE. 2012. Targeting mitochondria as a therapeutic target in cancer. J Cell Physiol 227:450–456.
90. Wettersten HI, Hakimi AA, Morin D, Bianchi C, Johnstone ME, Donohoe DR, Trott JF, Aboud OA, Stirdivant S, Neri B, Wolfert R, Stewart B, Perego R, Hsieh JJ, Weiss RH. 2015. Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis. Cancer Res 75:2541–2552.
91. Wu CP, Du HD, Gong HL, Li DW, Tao L, Tian J, Zhou L. 2014. Hypoxia promotes stem-like properties of laryngeal cancer cell lines by increasing the CD133+ stem cell fraction. Int J Oncol 44:1652–1660.
92. Wu Y, Meng X, Huang C, Li J. 2015. Emerging role of silent information regulator 1 (SIRT1) in hepatocellular carcinoma: A potential therapeutic target. Tumour Biol 4063–4074.
93. Xiao D, Ren P, Su H, Yue M, Xiu R, Hu Y, Liu H, Qing G. 2015. Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2. Oncotarget 6:40655–40666.
94. Xu K, Liu P, Wei W. 2014. MTOR signaling in tumorigenesis. Biochim Biophys Acta 1846:638–654.
95. Yin J, Park G, Lee JE, Park JY, Kim TH, Kim YJ, Lee SH, Yoo H, Kim JH, Park JB. 2014. CPEB1 modulates differentiation of glioma stem cells via downregulation of HES1 and SIRT1 expression. Oncotarget 5:6756–6769.
96. Yuan S, Wang F, Chen G, Zhang H, Feng L, Wang L, Colman H, Keating MJ, Li X, Xu RH, Wang J, Huang P. 2013. Effective elimination of cancer stem cells by a novel drug combination strategy. Stem Cells 31:23–34.
97. Zenobi R. 2013. Single-cell metabolomics: Analytical and biological perspectives. Science 342:1243259.
98. Zhu H, Wang D, Liu Y, Su Z, Zhang L, Chen F, Zhou Y, Wu Y, Yu M, Zhang Z, Shao G. 2013. Role of the hypoxia-inducible factor-1 alpha induced autophagy in the conversion of non-stem pancreatic cancer cells into CD133+ pancreatic cancer stem-like cells. Cancer Cell Int 13:119.